PAO Group Teams Up With Puration, Alkame, North American Cannabis Holdings On New CBD Nutraceuticals

PAO Group, Inc. PAOG, a holding company focused on alternative patient treatments, confirmed Friday it will launch a CBD Nutraceuticals line of products.

The company will create and sell new CBD nutraceuticals together with Alkame Holdings, Inc. ALKM, which will take on the role of co-packer, and North American Cannabis Holdings, Inc. USMJ whose team will help with distribution services.

PAOG is currently working on a CBD pharmaceutical product called RespRx as therapy for chronic obstructive pulmonary disorder. The product is derived from a patented cannabis extraction method.

CBD Nutraceuticals is expected to generate revenue this year, as the first three products will be launched during the fourth quarter of 2021:

• The first CBD nutraceutical, still in development, will be called CBD Relax-Rx and be used to treat anxiety and depression - a market projected to be worth around $18 billion by 2025.
• The second CBD product from the line, also in progress, is being developed from the company’s current research on the treatment of COPD, although separate from the pharmaceutical market.
• The third CBD nutraceutical being developed in collaboration with EVERx CBD Sports Water, which is owned by Puration, Inc.  PURA, will target the sports nutrition market.